HIKAL vs JAGSNPHARM: Stock Comparison
HIKAL is the larger company by market capitalisation. HIKAL shows a lower P/E and faster revenue growth, while JAGSONPAL PHARMACEUTICALS shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
HIKAL leads 4; JAGSNPHARM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| Live Price | ₹203.18 | ₹210.86 |
| Day Change | -3.6% | -3.24% |
| Volume | 3.29 L | 65,521 |
| 52-Week High | ₹261 | ₹264.5 |
| 52-Week Low | ₹146.25 | ₹155 |
| Distance from 52W High | -22.15% | -20.28% |
Valuation
| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| Market Cap | ₹2,501 Cr | ₹1,393 Cr |
| P/E Ratio | 0x | 30.83x |
| P/B Ratio | 2.09x | 5.11x |
| EPS | ₹-0.6 | ₹2 |
| Book Value | ₹97.23 | ₹41.95 |
| Dividend Yield | 0.28% | 1.84% |
Growth
| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | 37.3% | 9.6% |
| EPS Growth (TTM YoY) | 68.3% | 23.8% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| ROE | -4.07% | 15.6% |
| ROCE | -0.87% | 16.4% |
| Net Margin | -2.88% | 15% |
| Operating Margin | -0.95% | 20.38% |
| Debt to Equity | 0.57x | 0x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | HIKAL | JAGSNPHARM |
|---|---|---|
| Promoter Holding | 68.85% | 25.55%▲ 0.43 pp |
| FII Holding | 1.27%▲ 0.28 pp | 2.3%▼ 0.14 pp |
| DII Holding | 5.32%▼ 1.92 pp | 0.62%▲ 0.4 pp |
| Public Holding | 24.56%▲ 1.63 pp | 28.03%▼ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HIKAL and JAGSONPAL PHARMACEUTICALS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.